Overview The GUARDIAN Trial Status: Recruiting Trial end date: 2025-04-25 Target enrollment: Participant gender: Summary The treatments will be: 1) norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg, delayed resumption of chronic antihypertensive medications, and a target ward systolic pressure ≥110 mmHg (tight pressure management); or, 2) routine intraoperative blood pressure management and prompt resumption of chronic antihypertensive medications (routine pressure management). Phase: N/A Details Lead Sponsor: The Cleveland ClinicTreatments: EtomidateNorepinephrinePhenylephrinePropofolVasoconstrictor Agents